Overview

LYR-220 System for Adult Subjects With Chronic Rhinosinusitis (CRS)

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, and pharmacokinetics of two LYR-220 designs in symptomatic adult chronic rhinosinusitis (CRS) subjects who have had a prior bilateral total ethmoidectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Lyra Therapeutics